Early-onset psychosis · Psych Topics

Early-onset psychosis (EOP) is the clinical and service pathway for a first clear psychotic disorder with onset before age 18. It sits next to adult first-episode psychosis (FEP) and the schizophrenia spectrum monograph — but CAP examiners test developmental formulation, multi-informant assessment, autism/trauma traps, paediatric metabolic risk, school systems, parental consent, and a lower threshold for comprehensive organic work-up. Childhood-onset schizophrenia (COS / very-early-onset under 13) is rare and often severe; adolescent-onset presentations are more common and still carry substantial functional risk if DUP is long and care is fragmented.[4][9][17][19]

Overview and definition

EOP means frank psychotic symptoms of clinical severity — delusions, hallucinations, disorganised speech or behaviour, usually with functional decline — beginning before the 18th birthday, after reasonable exclusion of delirium and primary medical causes. The day-one label is often provisional (schizophrenia-spectrum psychosis, schizophreniform range, brief psychotic, affective psychosis, substance-associated, organic). Diagnosis is allowed to evolve with duration, mood chronology and course after reduced substance use.[4][7][8]

Very-early-onset / childhood-onset schizophrenia (VEOP / COS) conventionally means onset of schizophrenia before age 13. It is uncommon, highly heritable relative to later-onset forms, and frequently shows premorbid developmental and cognitive impairment. Adult-outcome data support substantial diagnostic stability for early-onset schizophrenia when carefully diagnosed.[17][19][20]

Duration of untreated psychosis (DUP) remains the modifiable clock from frank psychotic onset to adequate antipsychotic treatment. Longer DUP associates with poorer outcomes across first-episode cohorts — youth often present late because odd beliefs are misread as adolescence, autism, trauma, or substance use alone.[9]

[4] [7]

Classification

Age bands for very-early-onset schizophrenia under 13, early-onset psychosis under 18, and adult-onset FEP pathway — Figure 1. Age-based classificationAge cut-offs structure CAP language: VEOP/COS under 13; EOP under 18; adult FEP pathway typically peaks later.

VEOP / COS (under 13)

Rare; often severe progressive course
High heritability; premorbid developmental issues common
Intensify organic, genetic and developmental work-up
School and family systems dominate care planning

EOP (onset under 18)

Broader CAP pathway category
Includes schizophrenia-spectrum and evolving labels
Adolescent cannabis and peer risk prominent
Youth EIS / CAMHS-EIS interface

Adult FEP pathway

Peak late teens to twenties
Same multi-element EIS principles
Less parental consent machinery
See dedicated FEP topic for adult pathway depth

Clinical high risk / attenuated

Attenuated or brief limited symptoms
Most do not convert
Monitor, support function, substance advice
Do not start antipsychotics routinely without specialist rationale

DSM-5-TR vs ICD-11 pearl. Schizophrenia duration thresholds differ across manuals (ICD-11 emphasises at least 1 month of characteristic symptoms; DSM-5-TR uses continuous signs for at least 6 months including active-phase criteria). State which manual you are using in multi-board answers. Brief psychotic, schizophreniform and substance/organic categories still apply in youth when criteria fit.[4][8]

Epidemiology and risk factors

Headline EOP numbers

rare

COS under 13

severe end of spectrum

rises in adolescence

Incidence

male predominance earlier

longer = worse

DUP effect

Marshall systematic review

substantial

Adult stability

Hollis early-onset cohort

high at first Rx

Youth metabolic risk

Correll first-time SGA exposure

heterogeneous

Long-term course

Clemmensen synthesis

Childhood-onset schizophrenia is rare; rates climb through adolescence toward the adult peak. Risk factors examiners expect: first-degree family history of psychosis, obstetric and early neurodevelopmental hits, childhood adversity, urban upbringing, migration/social defeat, and — in adolescents — frequent high-potency THC cannabis. EU-GEI linked daily and high-potency cannabis use to variation in psychotic disorder incidence across Europe; after onset, continued cannabis predicts earlier relapse.[13][16][19]

Long-term outcome of early-onset schizophrenia is heterogeneous but often poorer on average than adult-onset illness, with functional disability concentrating when premorbid function is poor, negative symptoms dominate, and treatment is delayed or discontinuous.[17][18]

Pathophysiology

Progressive neurodevelopmental model of early-onset psychosis with striatal dopamine final common pathway — Figure 2. Mechanism sketch for EOPUpstream developmental hits converge on striatal dopamine dysregulation — the pharmacological target of early antipsychotics.

Progressive neurodevelopmental framing (COS literature). Childhood-onset schizophrenia is conceptualised as a severe, early expression of a progressive neurodevelopmental disorder, with evidence for abnormal developmental trajectories rather than a purely late-onset adult disease transplanted into a child.[19][20]

Dopamine hypothesis version III (Howes and Kapur). Upstream genetic, developmental and environmental factors converge on a final common pathway of striatal dopamine dysregulation. Excess presynaptic striatal dopamine synthesis and release links to positive symptoms and to D2 blockade efficacy. Prefrontal dopaminergic and broader network dysfunction helps explain negative and cognitive symptoms that pure D2 blockade often fails to fix.[12]

Why youth dosing and monitoring differ. First-episode and paediatric patients often respond at lower antipsychotic doses and are more vulnerable to extrapyramidal and metabolic adverse effects. First-time second-generation antipsychotic exposure in children and adolescents produces substantial early cardiometabolic risk — weight, BMI, glucose and lipids move fast; monitoring is not optional paperwork.[1][3][22]

Clinical presentation

Prodrome. Months of school drop-off, social withdrawal, sleep disruption, mood change, odd or over-valued ideas, and sometimes escalating cannabis. Not every odd adolescent is psychotic — use conviction, pressure, distress and functional collapse as anchors.[4][7]

Frank EOP. Positive symptoms dominate many exam stems: persecutory or referential delusions, auditory verbal hallucinations (commentary, arguing, commands), formal thought disorder, passivity phenomena. Negative and cognitive deficits are often already present and drive school failure. Affective symptoms may signal affective psychosis or comorbidity — chronology of mood versus psychosis is the discriminator.[4][19]

COS pattern examiners love. Insidious onset in a child with prior language, motor or social developmental concerns; progressive odd beliefs; deteriorating self-care; and family history of psychosis. Do not dismiss as "just autism" without a structured differential.[19][20]

Differential diagnosis

Win the CAP differential on developmental timeline, multi-informant history, trauma chronology, substance timeline, attention/fluctuation, and physical signs — not on a shopping list.[4][7]

Four-panel differential for early-onset psychosis: autism, trauma, substance, organic — Figure 3. CAP differential discriminatorsAutism, trauma, substance and organic causes are high-yield CAP traps — use discriminators, not synonym lists.

Autism spectrum

Lifelong social-communication pattern from early childhood
Stereotyped interests; concrete language; fantasy play
May have unusual beliefs without delusional conviction
New fixed false beliefs with functional collapse need psychosis work-up

Trauma / PTSD

Trauma timeline and triggers
Flashbacks, hyperarousal, dissociation
Content often trauma-linked
Can coexist with true psychosis — dual formulation

Substance-induced

Timeline locked to intoxication or withdrawal
High-THC cannabis, stimulants, synthetics
May resolve with abstinence or unmask primary illness
Urine screen supports never excludes

Organic / autoimmune

Fever, seizure, dysautonomia, movement disorder
Rapid cognitive change; catatonia
NMDAR and other encephalitides in youth
Investigate before chronic labelling

Also keep OCD with poor insight, bipolar mania with psychosis, severe depression with psychotic features, and personality-spectrum presentations in older adolescents on the board. Diagnostic overshadowing (assuming all odd behaviour is autism or trauma) is a classic CAP fail.[4][19]

Clinical and bedside assessment

Structure every EOP assessment the way examiners mark: safety, multi-informant history, development and school, DUP, MSE, risk, substance, capacity/parental consent, safeguarding, family system, and physical examination.[4][7]

Safety and observations (including capillary glucose).
Multi-informant history — child/adolescent, parents/carers, school, GP, previous CAMHS notes.
Developmental and educational history — language, social milestones, prior ASD/ADHD assessments, IQ/learning profile if available.
DUP calculation — date of first clear psychotic symptom to adequate treatment.
Full MSE with quoted examples of delusion and hallucination content (age-adapted).
Risk — suicide, self-harm, aggression, vulnerability, online exploitation, absconding, weapons, sibling risk.
Substance timeline with last use, potency and frequency.
Capacity and consent — Gillick/mature minor principles where applicable; parental responsibility; local Mental Health Act for under-18s (jurisdiction-specific; do not invent foreign section numbers).
Safeguarding — neglect, abuse, domestic violence, looked-after status.
Physical examination with neurological attention when red flags fire.[4][7]

[4]

Investigations

Baseline metabolic ECG checklist and red-flag special tests for early-onset psychosis — Figure 4. EOP work-up checklistBaseline metabolic and ECG work-up is mandatory before antipsychotics; special tests follow red flags and are broader in children.

[3] [4] [7]

Imaging and special tests when red flags fire or onset is very early/atypical: neuroimaging, EEG, LP and autoimmune encephalitis panel as directed, metabolic screens, and genetic testing when developmental phenotype or family history suggests. Urine drug screen supports the substance timeline but never excludes primary psychosis.[4][19]

Management — resuscitation of the acute crisis

De-escalate verbally; offer oral medication first; use intramuscular agents only when needed for safety; monitor airway, respiration, QTc and consciousness; never combine intramuscular olanzapine with a parenteral benzodiazepine; exclude hypoglycaemia and other organic drivers. Choose community youth EIS / CAMHS versus adolescent inpatient using risk, insight, family support and medical need — least restrictive setting that is still safe. Involve parents/carers early under privacy law; document safeguarding concerns.[4][7][8]

Management — definitive and stepwise

Youth early intervention multi-element care

Multi-element care hub for early-onset psychosis including medication family school substance and safety modules — Figure 5. Multi-element EOP careMulti-element youth care beats medication-only fragmented pathways — family and school are core modules.

Early intervention service principles from adult FEP trials transfer to youth services: coordinated specialty care improves outcomes versus fragmented treatment as usual, and multi-element packages (low-dose medication, family work, case management, psychological therapy access, substance and vocational/education support) are the exam-standard package.[10][11]

NICE guidance for children and young people with psychosis and schizophrenia and AACAP parameters emphasise comprehensive assessment, antipsychotic choice with monitoring, psychological and family interventions, and educational support — not a tablet alone.[4][7]

Core modules examiners expect you to name form part of multi-element youth early intervention rather than medication alone.[4][5][7][10][15]

Low-dose antipsychotic with metabolic/ECG monitoring from day one
Family psychoeducation / family intervention
School liaison and education plan
Individual psychological therapy access (including CBTp where available)
Assertive case management / care coordination
Substance use counselling (especially cannabis in adolescents)
Physical health monitoring
Crisis and relapse plan with means restriction when indicated
Supported education / vocational recovery as age-appropriate [4] [5] [7] [10] [15]

Antipsychotic start doses — start low

Start low, titrate to the minimum effective dose, and plan an adequate trial of roughly 4–6 weeks at a therapeutic dose with adherence support before declaring failure. Shared decision-making with the young person and family, plus side-effect education, drive adherence more than paternalistic high dosing.[1][4][5][22]

TEOSS (Sikich et al.). In early-onset schizophrenia spectrum disorders, molindone, olanzapine and risperidone showed comparable response rates in a double-blind comparison, with important side-effect differences (metabolic burden higher with olanzapine; EPS risk with the first-generation comparator). The practical pearl is efficacy at youth-appropriate dosing with agent-specific monitoring, not automatic high-dose polypharmacy.[1]

Aripiprazole in adolescents (Findling et al.). Oral aripiprazole demonstrated efficacy versus placebo in adolescents with schizophrenia in a multicentre randomised trial — a common first-line option when metabolic profile and once-daily dosing matter.[21]

TEA trial (Pagsberg et al.). In children and adolescents with first-episode psychosis, quetiapine XR versus aripiprazole showed broadly similar symptom efficacy with different adverse-effect profiles — reinforcing individualised choice and monitoring rather than a single "best drug for all."[6]

Agent (oral, illustrative youth FEP/EOP starts)	Typical start approach	Practical notes
Aripiprazole	Often about 2–5 mg daily initially in younger adolescents; many trials use 10 mg range; titrate carefully	Favourable metabolic profile relative to olanzapine; watch akathisia
Risperidone	Often 0.5–1 mg daily start; titrate toward low-to-moderate effective dose	Prolactin and EPS risk rise with dose
Olanzapine	Low start (e.g. 2.5–5 mg) when used; effective but high metabolic burden	Intensive weight/metabolic monitoring from first exposure
Quetiapine	Higher doses needed for antipsychotic effect if chosen	Sedation; metabolic effects; TEA evidence in youth FEP
		[1][3][6][21][22]

Exact licensed paediatric indications, age limits and product information vary by jurisdiction — state the agent, starting dose, titration plan, and monitoring, not a vague "start an atypical."[4][7][8]

Monitoring schedule (minimum in youth). Baseline as above; early clinical review within days; weight/BMI at every visit initially; metabolic recheck (glucose/HbA1c, lipids, BP) at intervals such as 1 month, 3 months, then regularly; ECG when risk factors or QT-risk drugs; prolactin if symptoms or high-risk agent; EPS/akathisia every visit. Akathisia is frequently misread as agitation or anxiety — examine before automatic dose increases or PRN sedatives.[3][4]

Family work and school liaison

Family psychoeducation and school liaison as core modules in early-onset psychosis care — Figure 6. Family and school modulesFamily intervention and school plans are treatment modules — not optional social work garnish.

Family intervention for schizophrenia-spectrum illness reduces relapse and hospitalisation risk in systematic review evidence. In EOP, family psychoeducation is non-negotiable: explain the illness model, early warning signs, communication patterns, medication adherence support, and how to respond without hostile criticism that raises expressed emotion.[15][4]

School is a clinical environment. Liaise with education for a written plan: reduced timetable if needed, quiet exam arrangements, anti-stigma briefing for staff who need to know, bullying response, and a reintegration pathway. Recovery is measured in attendance and learning as well as PANSS points.[4][7]

Substance — especially cannabis in adolescents

Counsel frequency, potency and continuation. Continued cannabis after onset associates with higher relapse risk in observational cohorts. Integrate motivational approaches with psychosis care; do not wait for perfect abstinence before treating psychosis.[13][16]

Clozapine threshold in refractory EOP

Algorithm from first low-dose antipsychotic trials to clozapine threshold in refractory early-onset psychosis — Figure 7. Clozapine thresholdAfter two adequate adherent failures, escalate to clozapine pathway — do not endless-cycle non-clozapine agents.

Kumra et al. In refractory early-onset schizophrenia, clozapine was superior to high-dose olanzapine in a 12-week randomised double-blind comparison — direct CAP evidence that clozapine belongs on the pathway after true treatment resistance, not as a mythical last resort delayed for years of polypharmacy.[2]

Practical fellowship stance aligned with AACAP, NICE and RANZCP principles: define adequate trials, escalate to clozapine after two failures, and treat LAIs as adherence tools not a substitute for the clozapine decision.[2][4][7][8]

Define an adequate trial: therapeutic dose, roughly 4–6 weeks, verified adherence, and side-effect management attempted.
After two adequate failures, escalate toward clozapine with full haematological and metabolic monitoring and family engagement — hand off detail of clozapine protocols to the clozapine monograph when needed, but name the threshold here.
Long-acting injectables may help adherence uncertainty earlier; they do not replace a clozapine decision when resistance criteria are met. [2] [4] [7] [8]

Relapse prevention and maintenance duration

Antipsychotic maintenance reduces relapse versus placebo across schizophrenia trials, and after a first episode medication discontinuation carries high recurrence risk in systematic review data. After remission of early-onset first-episode illness, plan guided maintenance rather than unsupervised early stop — commonly framed as at least 1–2 years after remission, longer if residual symptoms, prior relapse, high risk, or patient/family preference for security. Any deprescribing is a supervised experiment with a written early-warning plan and rapid reinstitution pathway.[14][8]

Specific subtypes and scenarios

Childhood-onset schizophrenia. Run full organic/developmental work-up; expect more negative/cognitive load; engage education intensively; keep clozapine pathway visible early if trials fail.[19][20]

Adolescent-onset FEP in CAP services. Same EIS multi-element package; cannabis secondary prevention; preserve education; transition planning to adult services.[4][11]

Affective early-onset psychosis. Mood chronology and family history steer bipolar or depressive psychosis pathways; antipsychotics may still be needed acutely while mood treatment is chosen carefully.[4]

Autism + new psychosis. Dual formulation; adapt communication; avoid diagnostic overshadowing; careful capacity assessment.[4][19]

Cannabis-associated adolescent psychosis. Dual formulation until course after reduced use clarifies primary versus substance-driven illness.[16]

Treatment-refractory EOP. Two adequate trials then clozapine consideration with monitoring infrastructure.[2]

Complications and pitfalls

Accelerated metabolic syndrome, diabetes risk and weight gain in youth (especially olanzapine), QTc prolongation, EPS, hyperprolactinaemia, akathisia mislabelled as agitation.[1][3]
Misdiagnosing autism or trauma as primary schizophrenia — or the reverse overshadowing.[4]
Missing encephalitis or other organicity.[4][19]
Declaring treatment failure after days at a token dose, or after non-adherence.[4]
Endless antipsychotic switches without clozapine when resistance criteria are met.[2]
Ignoring family and school domains while chasing dose numbers.[15][7]
Early unsupervised antipsychotic stop after a first good remission.[14]
Premature fatalism destroying engagement, or false reassurance delaying treatment.[4]

Prognosis and disposition

Adult-outcome data show substantial diagnostic stability for carefully diagnosed early-onset schizophrenia, with functional outcomes varying widely.[17] Systematic review of long-term early-onset schizophrenia outcomes finds heterogeneous but often significant residual disability — short DUP, better premorbid function, fewer primary negative symptoms, engagement with multi-element care, and reduced substance use improve the odds.[9][18]

Remission is symptom control; recovery includes school/roles, relationships and personal meaning. Disposition: youth EIS/CAMHS versus inpatient, then community intensity matched to risk, with crisis contacts, family involvement, and planned transition to adult services when age-appropriate.[4][7][10]

Special populations

Intellectual disability with psychosis. Adapted communication; baseline developmental formulation; careful capacity; avoid diagnostic overshadowing.[4]

Autism spectrum comorbidity. Discriminate lifelong ASD features from new psychotic symptoms; dual care plans.[4][19]

Indigenous and culturally diverse families. Cultural formulation, interpreter use, family structure respect; content of beliefs may be culturally shaped while form (conviction, distress, impairment) remains clinical.[8]

Looked-after children / safeguarding complexity. Multi-agency working; placement stability affects adherence and risk.[4]

Gender-diverse youth. Engagement, minority stress awareness, and standard psychosis pathway without diagnostic delay.[4]

Evidence, guidelines and regional differences

RANZCP schizophrenia and related disorders guidance emphasises comprehensive care, early intervention principles, physical health monitoring, family involvement, and thoughtful maintenance after first episode. Youth services branding varies by state and district — multi-element principles travel even when the logo does not. Local Mental Health Act provisions for minors are jurisdiction-specific.[8]

Landmark list to name in viva: TEOSS (Sikich), Findling aripiprazole, TEA (Pagsberg), Kumra clozapine refractory EOP, Correll cardiometabolic youth, Stafford youth interventions meta-analysis, AACAP McClellan, NICE Kendall summary, RANZCP Galletly, Marshall DUP, Hollis adult outcomes, Clemmensen long-term EOS, Rapoport/Gogtay COS neurodevelopment, Driver COS update, Correll EIS and RAISE for multi-element early care principles.[1][2][3][4][10][17]

Exam pearls

[2] [3] [4] [9]

CAPSTART

Self-test: 14-year-old with 3-month DUP, ASD history, and weekly high-THC cannabis

Working pathway: EOP with dual substance formulation and autism comorbidity — not automatic "just ASD." Multi-informant history, school collateral, organic/baseline bloods and ECG, safety plan. Start low-dose antipsychotic (e.g. aripiprazole with akathisia counselling) after baselines; family psychoeducation; school plan; cannabis motivational work; EIS/CAMHS coordination. State provisional diagnosis language. If two adequate trials fail later, escalate toward clozapine rather than polypharmacy stacking.[3][4][16][21]

[4] [7]

References

[1]Sikich L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study Am J Psychiatry, 2008.PMID 18794207
[2]Kumra S, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison Biol Psychiatry, 2008.PMID 17651705
[3]Correll CU, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
[4]McClellan J, Stock S, AACAP Committee on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with schizophrenia J Am Acad Child Adolesc Psychiatry, 2013.PMID 23972700
[5]Stafford MR, et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis PLoS One, 2015.PMID 25671707
[6]Pagsberg AK, et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised TEA trial Lancet Psychiatry, 2017.PMID 28599949
[7]Kendall T, et al. Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance BMJ, 2013.PMID 23344308
[8]Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders Aust N Z J Psychiatry, 2016.PMID 27106681
[9]Marshall M, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review Arch Gen Psychiatry, 2005.PMID 16143729
[10]Correll CU, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression JAMA Psychiatry, 2018.PMID 29800949
[11]Kane JM, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program Am J Psychiatry, 2016.PMID 26481174
[12]Howes OD, Kapur S The dopamine hypothesis of schizophrenia: version III--the final common pathway Schizophr Bull, 2009.PMID 19325164
[13]Di Forti M, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study Lancet Psychiatry, 2019.PMID 30902669
[14]Zipursky RB, Menezes NM, Streiner DL Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review Schizophr Res, 2014.PMID 23972821
[15]Pharoah F, et al. Family intervention for schizophrenia Cochrane Database Syst Rev, 2010.PMID 21154340
[16]Schoeler T, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study Lancet Psychiatry, 2016.PMID 27567467
[17]Hollis C Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity Am J Psychiatry, 2000.PMID 11007720
[18]Clemmensen L, Vernal DL, Steinhausen HC A systematic review of the long-term outcome of early onset schizophrenia BMC Psychiatry, 2012.PMID 22992395
[19]Driver DI, et al. Childhood-Onset Schizophrenia and Early-onset Schizophrenia Spectrum Disorders: An Update Child Adolesc Psychiatr Clin N Am, 2020.PMID 31708054
[20]Rapoport JL, Gogtay N Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder Int J Dev Neurosci, 2011.PMID 20955775
[21]Findling RL, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia Am J Psychiatry, 2008.PMID 18765484
[22]Gardner DM, et al. International consensus study of antipsychotic dosing Am J Psychiatry, 2010.PMID 20360319

Overview and definition

[4] [7]